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Abstract:
Role of Methyltransferase Like-3 (METTL3) in Pancreatic Ductal Adenocarcinoma (PDAC)
Progression
Bhargavi Brahmendra Barathi, B. Tech; Advisor: Dr. Anirban Maitra, MBBS

Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer with about a 10% five-year
survival rate. The grim prognostic situation of pancreatic cancer patients underlines the need to
identify novel molecular targets. Recent studies have brought to attention, the need to
therapeutically exploit epigenetic pathways, apart from only targeting genetic mutations to
effectively combat PDAC. To that effect, METTL3-mediated post-transcriptional methylation of RNA
transcripts have been shown to contribute to cancer progression in multiple cancer types.
METTL3 deposits methyl groups onto adenosine bases within specific consensus sequences in RNA,
resulting in the formation of N-6 methyl adenosine (m6A). m6A is the most abundant internal
modification in mRNA and affects gene expression while also playing crucial roles in early-stage
development, organogenesis, and cell-fate determination.
To investigate the effect of METTL3 in PDAC, we analyzed TCGA RNA-Seq expression profile data for
the PAAD patient cohort and found that METTL3 expression is positively correlated with patient
survival. The difference in median survival between patients expressing METTL3 at a higher level
than average compared to patients expressing low levels of METTL3 was 6 months. We generated
METTL3 knockdown clones of human pancreatic cancer cell lines (Panc-1 and MiaPaca-2) using
shRNA targeting and performed in vitro assays to determine differences in growth and migratory
characteristics upon METTL3 knockdown. METTL3 loss decreased proliferation and migration rates
in MiaPaca-2 cells and decreased proliferation rate in Panc-1 cells when compared to control cell
lines. As METTL3 is physiologically important in inducing differentiation and repressing pluripotent
identity, we investigated the effect METTL3 knockdown exerts on EMT-associated markers in these
pancreatic cancer cell lines. We found that in the epithelial cell line, Panc-1 upon METTL3
knockdown there was a reduction in E-Cadherin expression, along with a concordant increase in NCadherin and Vimentin expression. Our results indicate that expression of METTL3 positively
regulates patient survival in PDAC, reduces proliferation and migration rates of pancreatic cancer
cell lines, and induces an EMT-like phenotype.
vi
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1. Introduction:
1.1 Pancreatic Ductal Adenocarcinoma:
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive cancer of the exocrine section of the
pancreas with a grave 5-year survival rate of about 10%.(1) Even though the Surveillance,
Epidemiology, and End results (SEER) program of the National Cancer Institute only estimated PDAC
to be the eleventh most common cancer in the US in 2020, which accounted for 3.2% of total new
cancer cases, it was the third most leading cause of cancer-related deaths, that year. PDAC is also set
to become the second leading cause of cancer-related deaths, only behind lung cancers by 2030.(2)
Effective combative strategies to fight PDAC have been hindered due to a variety of factors. Lack of
symptoms in the early stages of the disease leads to it being detected at a later stage, contributing to
the bleak survival rate.(3) Progression of the disease occurs in distinct histopathological stages
involving the sequential activation or suppression of different oncogenes and tumor suppressors,
respectively. The most common pathological stage considered to be a precursor to adenocarcinoma
of the pancreas is the Pancreatic Intraepithelial neoplasia (PanIN) stage. PanINs are lesions occurring
in small pancreatic ducts that can only be observed under the microscope. Pathologists had originally
adopted three degrees of grading the PanINs (grade 1-3), but are now moving to a two-tiered system
being, low grade and high grade PanIN.(4),(5) Treating PDAC as a standard involves resecting the
tumor surgically, along with administering adjuvant chemotherapy.(5) One of the key impeding
factors to successful treatment has also been the development of therapeutic resistance to
chemotherapy.(6) Disease recurrence can occur by way of undetected micrometastasis, also leading
to a roadblock in treatment.(7)
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1.2 Causes and risk factors of Pancreatic Cancer:
1.2.1 Age
Though one singular cause of pancreatic cancer is unknown, there are a plethora of risk
factors that contribute to the development of the disease. Age is a known non-modifiable risk factor
in the pancreatic cancer narrative. The proportion of risk involved in developing pancreatic cancer is
in direct correlation with aging. Patients presenting with pancreatic cancer are usually older
individuals. Diagnosing the cancer in patients under thirty years of age is uncommon.(5),(8). 65 to 74
years of age is reported to be the most frequent window when pancreatic cancer is diagnosed in in
the United States, with a median age of 70.(1) The highest mortality rates are also reported within the
same 65-74 years window, with the median age at death being 72.(1)

1.2.2 Sex
Some of the demographic factors that contribute to an increased risk of pancreatic cancer are
sex and ethnicity. Men are, on average more likely to develop pancreatic cancer compared to
women.(1) According to the Global Cancer Observatory, in 2020, males across the globe had an agestandardized rate (ASR) of incidence of pancreatic cancer of 5.7, compared to women that had an ASR
of 4.1.(9) Although some studies suggest that this variation may be brought about by environmental
risk factors such as a higher prevalence of smoking among men, it is unlikely to be the sole cause.
Other host genetic factors that could potentially be contributing to this higher incidence in men are
yet to be uncovered.(10)

1.2.3 Ethnicity
Historically, racial differences have been attributed to display significant variation in
pancreatic cancer incidence and mortality rates. In the United States, patients of African American
origin report higher numbers when compared to Caucasians and Asian Americans.(8) Ashkenazi Jews
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are also known to possess a higher susceptibility to developing pancreatic cancer as a result of their
genetic make-up.(11),(12)

1.2.4 Smoking
Several studies have been conducted to determine the effects various environmental risk
factors exert on pancreatic cancer incidence. A conclusive detrimental relationship between smoking
and about two-fold increase in risk of developing pancreatic cancer has been established.(13),(14)
Independent studies on both animals and epidemiological data have confirmed that cigarette smoking
and tobacco are carcinogens, in the pancreatic context.(11) Some groups have reported a dosedependent effect to the number of cigarettes smoked and length of exposure, while some have
claimed an inconclusive correlation.(13) A 2012 study revealed that nicotine, one of the major
constituents of a cigarette, activates Src kinase promoting pancreatic cancer progression and
metastasis.(15) Alcohol consumption, on the other hand has not revealed a convincing correlation to
be a risk factor for pancreatic cancer incidence.(13)

1.2.5 Alcohol
The results from various studies determining the degree of risk alcohol poses to pancreatic
cancer incidence have been mixed and the field seems to be split on the verdict. However, alcoholism
or chronic overindulgence of alcohol is a major contributor to chronic pancreatitis, which is a welldocumented risk factor for PDAC incidence.(16) This warrants us to treat alcohol as a potential risk
factor for pancreatic cancer incidence and advocate for decreased alcohol consumption, as part of a
holistic lifestyle change.

1.2.6 Obesity
Obesity is an important pancreatic cancer risk factor that has a bearing on millions of people
across the globe, ever more so in a developed nation, such as the United States. Individuals with a
Body Mass Index (BMI) of greater than or equal to 30, are considered obese and possess a less than
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fivefold increase in risk of PDAC incidence.(12) A World Cancer Research Fund pancreatic cancer
report in 2012, referenced several studies that demonstrated a higher risk of pancreatic cancer in
obese individuals and showed that for increases in every 5 BMI units, the risk increased by 10%,
regardless of gender of the patient.(5) Obesity has also been associated with the onset of Type 2
diabetes, which is a known risk factor for pancreatic cancer.

1.2.7 Chronic Pancreatitis
Chronic pancreatitis (CP), as the name suggests, is an inflammation of the pancreas that
progresses over time. It is accompanied by acinar cell destruction, fibrosis, and an eventual inability
of the patient to digest food and secrete pancreatic hormones.(8),(17) CP is considered a risk factor
that predates pancreatic cancer in patients. Although it is a risk factor, there is considerable overlap
between most symptoms of the two conditions, making the diagnosis of pancreatic cancer
difficult.(13) Chronic pancreatitis can be caused by hereditary (somatic mutations), environmental
(alcohol or cigarette smoking), or idiopathic factors. It has been reported that when comparing alcohol
related chronic pancreatitis with genetic idiopathic chronic pancreatitis, the latter poses a higher risk
of pancreatic cancer.(18) Of all the chronic pancreatitis patients, when we monitor them over a 20year period, about 5% of them develop pancreatic cancer.(5),(19)

1.2.8 Genetic Factors
Pancreatic cancer, at the root of the disease is genetic and can be caused by inherited and
acquired mutations. Family history also plays a significant role as a risk factor contributing to
pancreatic cancer incidence, wherein it can be classified as familial incidence of the cancer. Familial
pancreatic cancer is defined as when two or more first-degree relatives of a patient currently have or
previously have been diagnosed with pancreatic cancer, in the absence of other known genetic
conditions.(5),(12) There is an exponential increase in risk with the number of first-degree relatives
involved that have pancreatic cancer. Specific familial genetic syndromes also contribute to an
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increased risk of developing pancreatic cancer, through germline mutations in certain genes. Some of
them include hereditary breast cancer (mutations in BRCA1, BRCA2), hereditary pancreatitis (PRSS1
gene is affected), familial atypical multiple-mole melanoma (p16/CDKN2A is mutated), and PeutzJeghers syndrome (STK11/LKB1 mutations).(5),(8),13,(20),(21)
A majority of the pancreatic cancer cases arise due to mutations that occur randomly, as
opposed to inherited familial cancer.(8) Though many hundreds of genes are mutated in a pancreatic
cancer tumor, variable across patients, a select list of genes have been identified to be common across
the patient population, believed to be driving this malignancy. They include mutations in well-known
cancer associated genes and other relevant signaling pathways. Collectively known as the genetic
drivers of PDAC, their expression patterns have been shown to denote the sequential
histopathological stages of the disease.(22)

1.3 Common genetic drivers of PDAC:
Mutations in the K-RAS oncogene were the first to be discovered as playing a role in
pancreatic cancer initiation.(23) Point mutations arising in codon 12 of the oncogene, activate it to
express a mutated form of the Ras protein. These mutations, substituting the glycine with now, valine,
aspartate, or arginine are detectable in about 30% of early neoplastic lesions and are almost
ubiquitous in advanced tumors.(22),(24) K-RAS mutations have been shown to be the earliest genetic
perturbation in the progression of PanINs in humans.(22) Activating oncogenic mutations in K-RAS
bring about downstream cellular effects promoting tumor growth by engaging different signaling
pathways including RAF-MAPK and PI3K.(22),(25),(26)
Loss of the CDKN2A gene and mutations in the tumor-suppressor P53 are also both commonly
observed in the later stage of PDAC progression.(25) Mutations in the P53 gene occur as missense
alterations in later stage PanINs. CDKN2A gene encodes two tumor suppressor genes at the 9q21
5

locus, INK4A and ARF. With the loss of CDKN2A, both INK4A and ARF are lost in most pancreatic
tumors.(23)
SMAD4 is also a frequently altered gene in pancreatic cancers, which is an important regulator of
the TGF-B signaling pathway. This mutation is observed in approximately half of the pancreatic
cancer population.(23)

Figure 1: Histopathological progression of pancreatic cancer with temporal expression of genetic
drivers. (Bardeesy, N. & DePinho, R. A. Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2,
897–909 (2002). Used with permission from Copyright Clearance Center. License number –
5038411365197)
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1.4 METTL3 and N-6 methyl adenosine (m6A):
Methyltransferase-like 3 (METTL3) is a 70kDa protein that is encoded by the METTL3 gene and
methylates RNAs, including but not limited to mRNA, tRNA, lncRNA.(27) METTL3 along with METTL14
and WTAP proteins forms the methyltransferase writer complex or the m6A-METTL complex (MAC
complex).(28) METTL3 acts as the methylator in the complex, and hence referred to as the writer.
METTL14 provides structural support to METTL3 but does not methylate RNA transcripts.(29) METTL3
catalyzes the addition of a methyl group onto specific adenosine residues in the RNA, forming N-6
methyladenosine. This methylation is not a stochastic process but occurs within identified consensus
motifs in the RNA. In the mRNA, the methylation is also preferentially enriched close to the stop
codon, 3’ UTR and long internal exons.(30) There are other key protein players in the methylation
cascade known as readers and erasers. Erasers reverse the methylation, reverting the molecule to an
adenosine once again. Readers, like the YTHDF and IGF2BP family of proteins recognize and bind to
the methyl mark to bring about downstream effects on gene expression. ALKBH5 and FTO are two key
demethylases considered erasers of this modification.(31),(32)

6

m A writer

6

m A eraser

Adenosine

N-6 Methyladenosine

Figure 2: Chemical structures of METTL3-mediated m6A RNA methylation
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1.5 Physiological effects and functions of METTL3 mediated m6A RNA methylation

m6A RNA methylation leads to a variety of effects on gene expression. Reader proteins are
recruited to the methylation site that can then recognize and bind to effect these downstream
changes. mRNA structure, mRNA splicing, mRNA half-life, mRNA export, and mRNA translational
efficiency are influenced by the deposition of m6A marks.(32) YTHDF1 increases translational
efficiency of methylated RNA transcripts while YTHDF2 reduces half-life of methylated transcripts.
These are two key downstream effects of the m6A RNA methylation that have the most significant
bearing on the human transcriptome.
From previously published studies understanding normal physiology, we know that METTL3
plays a key role in regulating early embryogenesis,(33) circadian rhythm of metabolic processes,(34)
innate immunity,(35) and long-term memory(36) among a whole host of other functions. An
important contribution of METTL3 and its associated methylation is the role it plays in early
development and cellular differentiation. Geula et al. showed that METTL3 is important in regulating
the transition of naïve pluripotent cells to differentiating towards a specific lineage. They cultured
mouse embryonic stem cells (mESC) from a mouse with a METTL3 knockout (KO) and outlined that
when conditioned to develop into a specific lineage, the cells still showed sustained expression of
pluripotent factors, failing to differentiate.(37)
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Figure 3: Embryonic stem cells with METTL3 knockout maintain pluripotent identity and fail to
differentiate into a specific lineage.
(Geula, S. et al. m6A RNA methylation facilitates resolution of naive pluripotency toward
differentiation. Science (80-. ). 347, 1002–1006 (2015). Used with permission form Copyright
Clearance Center. License – 5035930693527)
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1.6 METTL3 and m6A methylation in cancer:
METTL3 expression and METTL3-mediated m6A RNA methylation have been recently
uncovered to be playing critical roles in a variety of different cancers. METTL3, according to previous
work by other groups can affect malignancies by playing tumorigenic or tumor suppressive roles, both
directly by expression of the protein and/or deposition of the methyl mark on specific RNA transcripts.
In most of the cancers where researchers have elucidated the mechanism as to how METTL3
affects the pathogenesis of that cancer, we can note that METTL3 methylates specific RNAs, modifying
them post-transcriptionally to now contribute to the carcinoma. For example, in lung
adenocarcinoma, METTL3 mediated m6A methylation on YAP, TAZ genes increase their translational
efficiency, leading to an elevated expression. This elevation in expression increases cell proliferation
and invasion. The normal physiological downstream effect of increase in translation when m6A
methylation occurs is exploited by cancer cells to further their cause.(38) Similarly, in acute myeloid
leukemia, there occurs a preferential increase in methylation in genes regulating apoptosis and
differentiation, like MYC, BCL2, and PTEN.(39) As these examples showcase, in both these cases
METTL3 plays a tumor promoting role and aids in the progression of the cancer.
On the contrary, the overall survival of renal cell carcinoma (RCC) patients showed a positive
correlation to METTL3 expression levels. Additionally, there was an increase in proliferation and
migration in RCC cell lines when METTL3 was knocked down. Xiao et al noted that METTL3 acts as a
tumor suppressor in renal cell carcinoma by potentially affecting the PI3K/Akt/mTOR pathway.(40) In
PDAC, however METTL3 and/or METTL3 mediated m6A methylation affects the progression of the
cancer is not known.
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1.7 METTL3 and Epithelial to Mesenchymal Transition in cancer:
One of the noteworthy ways in which METTL3 affects cancer progression is by methylating
specific transcripts involved in key pathways, contributing to cellular proliferation and survival of the
tumor. In Hela cells, the increased abundance of m6A marks on Snail mRNA induces translation and
drives the cells towards epithelial to mesenchymal transition (EMT).(41) EMT is a phenomenon of
cancer cells wherein which they lose epithelial characteristics while acquiring mesenchymal
characteristics, allowing them to migrate and form secondary tumors or metastasis.(42) This is
induced by the repression of specific proteins conferring an epithelial state (E-Cadherin, Occludin,
Claudin, Cytokeratin) and the activation of proteins associated with the mesenchymal state (NCadherin, Vimentin, Fibronectin).(42) While cancer cells undergo EMT, they also acquire stem-cell like
features. METTL3 expression as detailed above, is important in the repression of pluripotent identity.
These factors present the need to explore the role METTL3 and m6A methylation play in the induction
of EMT in cancer.
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Figure 4: Epithelial to Mesenchymal Transition in Cancer
(Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal
transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69-84.
doi:10.1038/s41580-018-0080-4. Used with permission from Copyright Clearance Center.
License – 5058391407002)
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2. Hypothesis and aims:
The proportion of pancreatic cancer incidence rates to the mortality rates every year in the US is
almost close to 1, showcasing the aggressive nature of the cancer. The disease is invariably fatal with
only 9.3% of patients having survived beyond the 5-year mark between 2009 and 2015 according to
the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute.
Treatment options, though have continuously evolved, over the last few decades, there has only been
a marginal increase in survival rates. Given the heterogeneity in treatment outcomes among
pancreatic cancer patients, there is a timely clinical need to investigate novel genes and molecular
signaling pathways.
In understanding the influence of epigenetic modifications on cancer initiation and progression,
various groups have implicated RNA methyltransferase, METTL3 in a slew of different cancers.
METTL3 adds a methyl molecule onto specific adenosine residues in the RNA, giving rise to the
modification, N-6 methyl adenosine (m6A). Both METTL3 and m6A, depending on the cancer context
have been shown to play tumorigenic and tumor-suppressive roles. In the case of PDAC, the role of
METTL3/m6A methylation and the mechanisms of how it affects pancreatic cancer are not known.
We sought to answer the above question to address this gap of knowledge.
Based on our findings from investigating the relationship between METTL3 expression and overall
pancreatic patient survival from TCGA, we hypothesized that METTL3 expression impacts pancreatic
cancer progression. The specific aims designed to test this hypothesis were as follows:
Aim 1: To investigate the effect of METTL3 on proliferative and migratory characteristics of
pancreatic cancer cells
Aim 2: To assess the effect of METTL3 loss on EMT-associated markers in pancreatic cancer cells
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3. Materials and Methods:
3.1 Analyzing TCGA dataset:
METTL3 FPKM values of 156 patients in the TCGA PAAD cohort were analyzed against the
clinical information from UC Xena. Based on average METTL3 expression, the patient cohort was
divided into two groups: high METTL3 expressing and low METTL3 expressing. Kaplan Meier curves
were plotted to determine the correlation between METTL3 expression and patient survival, with
available clinical data. Patients with neuroendocrine carcinoma, mucinous adenocarcinoma, or any
other categorization of the disease were removed from consideration in the cohort, as we strictly
looked at PDAC patients. The METTL3 expression levels were also correlated with other relevant
clinical information using statistical tools.

3.2 Cell lines/cell culture:
Human pancreatic cancer cell lines Panc-1, MiaPaca-2 and mouse PKCY cell lines were used in
this study. The human lines were obtained from ATCC and cultured in Dulbecco’s modified eagle
medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 1x Penicillin-Strep (P/S)
solution. Mouse PKCY cell lines were cultured from harvested pancreases of PKCY mice maintained as
part of the lab’s animal protocol. These 2D mouse cell lines were also cultured in DMEM
supplemented with 10% FBS and 1x P/S solution.

3.3 Plasmid Production:
Bacterial stocks of MISSION shRNA targeting human and mouse METTL3 were purchased from
Sigma. The bacterial stock was streaked onto an agar plate using sterile techniques and allowed to
incubate at 37 degree Celsius for 12-16 hours. Bacterial colonies that grew on the plate were picked
and inoculated in LB broth of 5ml volume and allowed to shake in a temperature-controlled shaker
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for 12-16 hours overnight at 37 degree Celsius. Plasmid was isolated from a portion of the starter
culture using a mini-prep kit and sent for sanger sequencing to confirm the identity of the genetic
sequence. The remaining starter culture was used to inoculate a bigger volume of LB broth to obtain
more plasmid DNA using the maxi-prep kit as was appropriate according to the initial volume of the
culture. Plasmid DNA that was obtained was stored at -20 degree Celsius and used for lentivirus
production.

3.4 Lentivirus Production:
To produce lentivirus carrying the appropriate transfer plasmid (targeting human or mouse
METTL3 in this context), we used HEK293T cells. A low passage number of HEK293T cells were plated
and cultured in complete media containing DMEM, 10% FBS, 1x P/S, and 1mM sodium pyruvate for
about 20-24 hours. The media was then changed to antibiotic-free media, followed by addition of the
transfection mix to the plate. The transfection mix included the lentiviral packaging plasmid (psPAX2),
the lentiviral envelope expressing plasmid (pMD2.G - VSV-G) and our desired transfer plasmid in a
solution containing Opti-MEM and lipofectamine 3000. The cells were allowed to incubate with the
transfection mix overnight, before changing the media back to complete media. The supernatant
produced by the cells, which constituted the lentivirus produced was centrifuged, filtered, and flash
frozen 48h later for further use.

3.5 Transfection:
The transfection protocol was adapted from Addgene to generate stable cell lines expressing
our gene of interest (a knocked down version of the METTL3 gene in this case). Five different lentiviral
dilutions were created in a 6-well plate with DMEM complete media containing 10ug/ml polybrene,
along with a no-virus control. DMEM complete media constituted of DMEM with 10% FBS, 1x P/S, and
4mM L-alanyl-L-glutamine. A reverse transduction was performed by seeding 50,000 cells into each
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well of the 6-well plate, that already contained 0.5ml of the different lentiviral dilutions. The cells
were incubated with the virus for 48-72h and monitored by observing under the microscope each day.
Post the incubation, the media was changed to contain media containing puromycin to start the
selection process. The no-virus control well was used to monitor the death of the cells and gauge the
rate of selection in other wells. A particular well with the appropriate dilution of virus was selected
based on the degree of cell killing using Poisson statistics principles to ensure that only one copy of
the virus is incorporated into majority of the cells transfected. Once confluent, the growing polyclonal
population of resistant cells in the selected well was expanded into a 10cm dish and further on in
bigger plates. The polyclonal population obtained was tested for protein expression using Western
Blotting and single-cell clones were created from them using a limiting dilution technique.
Panc-1 and MiaPaca-2 cell lines were transfected with lentivirus containing shRNA sequence
targeting the human METTL3 gene. Polyclonal and single-cell clones from them were obtained using
the above-described protocol. This work was carried out by Dr. Fredrik Thege in the Andrew Rhim lab.
Mouse PKCY lines were transfected with lentivirus containing shRNA sequence targeting the mouse
METTL3 gene. Polyclonal populations from different mouse lines were created by the same protocol
by this author.
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Sigma MISSION

Sequences of shRNA used

Species

shRNA

targeted
by
shRNA

TRCN0000039110 CCGGGCAGAGCAAGAGACGAATTATCTCGAGATAATTCGTCTCTTGCTCTGCTTTTTG
(referred to as
shRNA 110)

Mouse

TRCN0000039111 CCGGCCTCAGTGGATCTGTTGTGATCTCGAGATCACAACAGATCCACTGAGGTTTTTG Mouse
(referred to as
shRNA 111)

TRCN0000039112 CCGGCGTCAGTATCTTGGGCAAATTCTCGAGAATTTGCCCAAGATACTGACGTTTTTG

Mouse

(referred to as
shRNA 112)

TRCN0000039113 CCGGGCACCCGCAAGATTGAGTTATCTCGAGATAACTCAATCTTGCGGGTGCTTTTTG Mouse
(referred to as
shRNA 113)

TRCN0000289812 CCGGCGTCAGTATCTTGGGCAAGTTCTCGAGAACTTGCCCAAGATACTGACGTTTTTG
SHC002

CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT

Human
Nontargeted
control

Table 1: Description of different test shRNA plasmid sequences targeting METTL3

17

3.6 Western Blotting:
Panc-1 and MiaPaca-2 METTL3 knockdown cell lines were plated in 6-well plates 48h prior to
protein collection and allowed to grow to confluency. Protein lysates were collected from the cells by
cell scraping upon addition of RIPA buffer. RIPA buffer was prepared by adding 1x volume of protease
inhibitor. 60ul of RIPA buffer was used per well of a 6-well plate. Protein lysate obtained was shaken
and mixed using a rotor at 4 degree Celsius for 45 minutes. The lysate was then centrifuged at 15000g
for 10 minutes to remove debris. Protein supernatant obtained was quantified using Bio Rad DC
Protein Quantification Assay.
Total protein of 15ug was loaded into each well and a 4-15% BioRad gradient gel was used.
We ran the gel at 60V for the first ten minutes and at 90V for the remainder of the time. Once the gel
was separated enough (indicated by the Bio Rad Precision Plus Dual Color Standards Ladder), transfer
to a PVDF membrane was carried out through the Bio Rad Trans-Blot Turbo Transfer system at a mixed
setting of 25V, 7 min. Prior to transfer, the PVDF membrane was equilibrated in 1x Trans-Blot Turbo
Transfer buffer and methanol for activation.
Post transfer, the membrane was blocked for 2 hours at room temperature using 3% BSA in
TBST. 1:2000 concentration of the primary anti-rabbit Abcam METTL3 antibody (EPR 18810; ab
195352) was used, and the membrane was incubated overnight at 4 degree Celsius. The membrane
was washed the next day thrice with TBST and incubated for 50 minutes at room temperature in
1:2000 concentration of dilute HRP secondary antibodies. Post incubation, the membrane was
washed thrice again in TBST and imaged using Bio Rad’s Clarity ECL chemiluminescent substrate. The
gel images obtained on the Chemi Doc were processed using image analysis software, Fiji - Image J.
Primary Antibodies used to determine EMT expression levels were Cell signalling systems anti-rabbit
E-Cadherin at 1:1000 concentration, Cell Signalling systems anti-rabbit Vimentin at 1:1000
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concentration, and BD Biosciences anti-mouse N-Cadherin at 1:1000 concentration. B-actin or Hsp90
were used as internal loading controls, based on the size of the desired protein product.
The same western blotting protocol was used on the PKCY mouse METTL3 knockdown cell lines as
well.

Antibody
METTL3

Clone
EPR 18810; ab

Host species

Concentration

Manufacturer

Rabbit

1:2000

Abcam

Rabbit

1:1000

Cell Signaling

195352
E-Cadherin

24E10 mAb
#3195

N-Cadherin

32/N-Cadherin

systems
Mouse

1:1000

BD Biosciences

Rabbit

1:1000

Cell Signaling

RUO
Catalog no. 610920
Vimentin

D21H3 mAb #
5741

systems

Table 2: Description of the various antibodies used in this study
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3.7 Quantitative Polymerase Chain Reaction:
Panc-1 and MiaPaca-2 METTL3 knockdown cells were plated in 6-well plates 48h prior to RNA
extraction and allowed to grow to confluency. RNA lysates were collected from the cells by adding
RLT buffer followed by cell scraping. The lysates were collected with the samples and buffers being
kept on ice, to minimize RNA degradation. RLT buffer was prepared by adding 10ul B-mercaptoethanol
for every 1000ul volume of buffer. The collected lysates were passed through a 25–27-gauge syringe
about ten times to thoroughly homogenize the sample. The lysate was then passed through the
Qiagen RNeasy mini kit column to isolate purified RNA. Isolated RNA was quantified using the
Nanodrop 2000 to determine purity and concentration.
2ug of isolated RNA was used to create cDNA using the Invitrogen Super Script Reverse
Transcriptase III. 25-50ng/ul of generated cDNA was used in setting up the qPCR assay. Thermo
Fisher’s Power SYBR Green Master Mix was used to make the working solution with cDNA along with
appropriate primers. The reaction was set up in a 96-well plate and run according to manufacturer’s
instructions. Relative gene expression was measured using the standard (delta (delta Ct)) comparison.
Human beta-2-microglobulin was used as housekeeping internal control gene.

3.8 Proliferation Assay:
3000 cells/well were plated in 96-well plates in to assess the proliferative characteristics of
Panc-1 and MiaPaca-2 METTL3 knockdown cell lines. 1x concentration of Incucyte NucRed was also
added to the cells while plating as a nuclear stain to aid in the cell count. The plate was set up on an
imaging schedule and the cells were allowed to grow in the Incucyte. Phase confluence and red object
count images were taken every 4 hours for 5 days. After the completion of the 5 days, data collected
was used to plot a growth curve of time vs cell count in knockdown and control conditions of these
cell lines. Doubling times calculated from the growth curve statistics was used as a measure of
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proliferative ability. Three independent experiments were conducted reproducibly, making it a
sample size of n=3.

3.9 Transwell Migration Assay:
Transwell migration assay was performed to determine the migration rates of Panc-1 and
MiaPaca-2 cell lines upon METTL3 knockdown. This assay measures the chemotactic ability of the cells
migrating towards a chemo attractive gradient. Falcon Permeable Support for 6-well plate with 8.0um
Transparent PET membrane sterile inserts from Corning were used in this study. 300000 cells/well
were plated on top of the transwells in serum-free DMEM media (containing 1x P/S antibiotic) and
allowed to migrate to the other side of the transwell. A chemo attractive gradient of serum was
created by adding DMEM with 10% FBS (also containing 1x P/S antibiotic) on the other side of the
transwell, making sure the media touches the membrane on the transwell on top of the well. Panc-1
and MiaPaca-2 cells were tested and optimized to migrate for 24h and 16h, respectively prior to the
experiment. Once the appropriate incubation times for each cell line were elapsed, media on top of
the inserts were aspirated and the transwell was moved to a new plate. A cotton-tipped applicator
was used to remove any remaining media and cells that may not have migrated from the top of the
transwell. Fixing/staining solution was added to the underside of the transwell insert, now placed in
a new plate, and allowed to incubate at room temperature for 15 minutes. Post incubation, the
transwells were washed and allowed to dry, followed by imaging them on a microscope and counting
the fraction of migrated cells. Composition of the fixing/staining solution is as follows:
0.5g Crystal Violet (0.05% w/v)
27ml 37% Formaldehyde (1%)
100ml 10x PBS (1x)
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10ml Methanol (1%)
863ml Distilled water to make up volume to 1L

3.10 Statistical Analysis:
GraphPad Prism version 8 was used to statistically analyze the results obtained. Error bars
represent standard error of the means. P-value ≤ 0.05 were considered statistically significant. N=3
was the sample size for experiments unless specified otherwise.
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4. Results:
4.1 METTL3 expression is positively correlated with survival in PDAC patients:
To determine the correlation between overall survival and METTL3 expression levels in PDAC
patients, METTL3 FPKM values from the TCGA-PAAD cohort and clinical information from USC Xena
were used. The patient cohort, based on the average level of METTL3 expression was split into two
groups – high METTL3 expressing, low METTL3 expressing. Based on the clinical survival data
available, a Mantel-Cox (log rank) test was performed to analyze overall survival as a function of
METTL3 gene expression levels. A Kaplan-Meier curve was plotted to visualize the correlation
between survival and METTL3 expression levels. We found that the patient cohort expressing higher
levels of METTL3 than average, tended to survive longer than the patient cohort lower than average
levels of METTL3. The difference in median survival was 6 months significantly longer in the patient
group that showed higher than average levels of METTL3. P-value for the log rank test was 0.04,
which rejects the null hypothesis that both survival curves are not significantly different. We thus
found that METTL3 expression positively correlated with survival. Median survival in days for each
patient group is indicated in table 3.
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Figure 5: Analyzing TCGA PAAD Cohort Data - Kaplan-Meier curve depicting the correlation
between overall survival rates and METTL3 expression in PDAC patients. Patients expressing high
and low levels of METTL3 are shown in red and green, respectively.

Patient group

Median
Survival
(days)

High METTL3 expressing

691

Low METTL3 expressing

511

Table 3: Median survival of high METTL3 expressing group is higher than the low METTL3
expressing group by 6 months
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4.2 Generating METTL3 knockdown cell lines:
To investigate the effect of METTL3 on the proliferative and migratory properties of human
pancreatic cancer cells, we set out to generate a cellular system devoid of METTL3 expression. Panc1, MiaPaca-2 and PKCY mouse cell lines were lentivirally transfected with the appropriate shRNA
targeting human or mouse METTL3 gene using the adapted Addgene transfection protocol as
described in the materials section. Dr. Fredrik Thege created single-cell clones from the transfected
polyclonal populations of Panc-1 and MiaPaca-2 cell lines. The single-cell clones generated were
assigned numbers and would from hereon be described as follows:
Clone generated

Nomenclature
assigned

Panc-1 METTL3 KD Clone 2

PC2

Panc-1 METTL3 KD Clone 4

PC4

Panc-1 METTL3 KD Clone 5

PC5

Panc-1 METTL3 KD Clone 6

PC6

Panc-1 Non-targeted control

PNT

MiaPaca-2 METTL3 KD Clone 5

MC5

MiaPaca-2 METTL3 KD Clone 6

MC6

MiaPaca-2 METTL3 KD Clone 7

MC7

MiaPaca-2 METTL3 KD Clone 11

MC11

MiaPaca-2 Non-targeted control

MNT

Table 4: Nomenclature assigned to the different knockdown clones generated
Pancreases of mice with genotype p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY) were harvested
and cultured to generate mouse METTL3 knockdown pancreatic cancer cell lines. In these mice, cre
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expression (C) is driven under the pancreas-specific p48 promoter that allows for the expression of
mutant G12D Kras (K), loss of the P53 allele (P), and expression of the lineage label marker YFP (Y).
Mice containing these four alleles are hence termed PKCY mice. Mice with identifiers as described in
Table 5 were utilized. Single-cell clones were not generated from these murine METTL3 knockdown
polyclonal populations.
Mouse number

Genotype

14292

p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY)

16686

p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY)

17315

p53 L/L Kras G12D p48Cre Rosa Y/Y (PKCY)

Table 5: Identifier and genotype of the mice used to generate PKCY METTL3 knockdown cells

Figure 5 and 6 as follows showcase the morphology of the MiaPaca-2 and Panc-1 METTL3 KD single
cell clones respectively. MiaPaca-2 cells are mesenchymal-like cells with an elongated morphology.
Panc-1 cells on the other hand are epithelial-like cells that are polygonal, adherent and exhibit a
cobblestone like morphology. Panc-1 cells upon METTL3 KD do not exhibit a characteristic change in
morphology, compared to the non-targeted control. Whereas MiaPaca-2 cells seem to become less
elongated and more clustered, almost exhibiting an epithelial-like morphology compared to control,
when METTL3 is knocked down.
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MC5

MC6

MC7

MC11

NT Control
Figure 6: Morphology of MiaPaca-2 METTL3 knockdown single cell clones
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PC2

PC4

PC5

PC6

NT Control
Figure 7: Morphology of Panc-1 METTL3 knockdown single cell clones
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4.3 Confirmation of METTL3 knockdown:
4.3.1 Western Blotting:

PC2

A

PC4

PC5

PC6

PNT

METTL3

70kD

B-ACTIN

42kD

p=0.0013; **
p<0.0001; ****
p<0.0001; ****
B

p<0.0001; ****

METTL3 Expression

1.0
0.8
0.6
0.4
0.2
0.0
PC2

PC4

PC5

PC6

PNT

hMETTL3 KD Panc-1 Clones
Figure 8: Confirmation of METTL3 knockdown in Panc-1 cells using Western Blotting
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A) Western blot denotes a decreased level of METTL3 expression in the Panc-1 single cell
clones compared to the non-targeted control
B) Bar graph indicates the level of METTL3 expression in the different Panc-1 single cell clones
upon METTL3 knockdown

To test the level of METTL3 expression in the cellular system generated, we performed western
blotting. Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population were
tested for the knockdown in expression levels of METTL3 using Western Blotting. Western blots
imaged were quantified to determine expression levels of METTL3 using Fiji Image J. The bar graphs
indicate level of METTL3 expression the clones express post the knockdown. Average knockdown
levels of METTL3 expression determined by obtaining protein from three different passages (n=3) are
as follows. Average knockdown levels here indicate the level by which METTL3 expression was
reduced in these clones, as shown:

AVG METTL3 KD%

PC2

PC4

PC5

PC6

75%

86%

92%

71%

All Panc-1 METTL3 knockdown single cell clones show significantly reduced expression of
METTL3 when compared to non-targeted control using a t-test.
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MC5

A

MC6

MC7

MC11

MNT

METTL3

70kD

B-ACTIN

42kD

p<0.0001; ****
p=0.0004; ***

B

p<0.0001; ****
p<0.0001; ****
METTL3 Expression

1.0
0.8
0.6
0.4
0.2
0.0
MC5

MC6

MC7

MC11

MNT

hMETTL3 KD MiaPaca-2 Clones
Figure 9: Confirmation of METTL3 knockdown in MiaPaca-2 cells using Western Blotting
A) Western blot denotes a decreased level of METTL3 expression in the MiaPaca-2 single cell
clones compared to the non-targeted control
B) Bar graph indicates the level of METTL3 expression in the different MiaPaca-2 single cell
clones upon METTL3 knockdown
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To test the level of METTL3 expression in the cellular system generated, we performed western
blotting. Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population
were tested for the knockdown in expression levels of METTL3 using Western Blotting. Western
blots imaged were quantified to determine expression levels of METTL3 using Fiji Image J. The bar
graphs indicate level of METTL3 expression the clones express post the knockdown. Average
knockdown levels of METTL3 expression determined by obtaining protein from three different
passages (n=3) are as follows. Average knockdown levels here indicate the level by which METTL3
expression was reduced in these clones, as shown:

AVG METTL3 KD%

MC5

MC6

MC7

MC11

73%

74%

81%

85%

All MiaPaca-2 METTL3 knockdown single cell clones show significantly reduced expression of
METTL3 when compared to non-targeted control using a t-test.
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4.3.2 Quantitative Polymerase Chain Reaction:

p=0.0008; ***

Relative METTL3 Expression

p=0.0004; ***
p=0.0039; **

1.5

p=0.029; *
1.0

0.5

0.0
PC2

PC4

PC5

PC6

PNT

hMETTL3 KD Panc-1 Clones
Figure 10: Confirmation of METTL3 knockdown in Panc-1 cells using qPCR
Bar graph indicates the level of METTL3 expressed by the Panc-1 single cell clones post shRNA
knockdown of METTL3
Single-cell clones generated from the Panc-1 METTL3 knockdown polyclonal population were
tested for the knockdown in expression levels of METTL3 using quantitative polymerase chain reaction
(qPCR). Average knockdown levels determined by obtaining protein from three different passages
(n=3) are as follows:

AVG METTL3 KD%

PC2

PC4

PC5

PC6

63%

62%

60%

50%
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p=0.0017; **

Relative METTL3 Expression

p=0.0006; ***
p<0.0001; ****

1.5

p<0.0001; ****
1.0

0.5

0.0
MC5

MC6

MC7

MC11

MNT

hMETTL3 KD MiaPaca-2 Clones
Figure 11: Confirmation of METTL3 knockdown in MiaPaca-2 cells using qPCR
Bar graph indicates the level of METTL3 expressed by the MiaPaca-2 single cell clones post shRNA
knockdown of METTL3
Single-cell clones generated from the MiaPaca-2 METTL3 knockdown polyclonal population
were tested for the knockdown in expression levels of METTL3 using quantitative polymerase chain
reaction (qPCR). Average knockdown levels determined by obtaining protein from three different
passages (n=3) are as follows:

Avg METTL3 KD%

MC5

MC6

MC7

MC11

76%

80%

83%

90%
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4.4 Proliferation assay
4.4.1 METTL3 knockdown reduces proliferation rates in some Panc-1 clones

2d 0h

4d 0h

PNT

PC6

PC5

PC4

PC2

0d 0h

Figure 12: Proliferation assay in Panc-1 cells - This figure shows the growth of Panc-1 METTL3
knockdown clones imaged on a time course. The cells appear red upon incorporation of the Incucyte
NucRed dye to aid in cellular counts.
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Panc-1 METTL3 knockdown clones were plated in 96-well plates in duplicates in three
independent experiments and allowed to grow in the Incucyte, while being imaged every 4 hours for
5 days. Incucyte NucRed fluorescent dye was added to aid in cellular count. Using the NucRed dye as
a marker to label nuclei, cellular counts over 5 days were used to plot growth curves. Population
doubling times were extracted from the growth curves, using the exponential growth curve equation.
The population doubling times as compared against the non-targeted control are as follows:

Population

PC2

PC4

PC5

PC6

PNT

28.7

27.3

31.3

30.1

26.5

Doubling Time (h)

While population doubling time of clones 5 and 6 (PC5, PC6) were significantly slower
than the non-targeted control, doubling times of clones 2 and 4 were not significantly
different from the non-targeted control. We observed that METTL3 knockdown, hence
reduces proliferation rates in some METTL3 knockdown clones but not the others in Panc-1
cells.
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B

Figure 13: METTL3 knockdown reduces proliferation rates in some Panc-1 single cell clones
A) Growth curve denotes the rate of proliferation in Panc-1 clones upon METTL3 knockdown
compared to non-targeted control
B) Doubling times of Panc-1 METTL3 knockdown clones extracted from the growth curve are
depicted in this graph
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4.4.2 METTL3 knockdown reduces proliferation rates in MiaPaca-2 cells

2d 0h

4d 0h

MNT

MC11

MC7

MC6

MC5

0d 0h

Figure 14: Proliferation assay in MiaPaca-2 cells - This figure shows the growth of METTL3
knockdown clones imaged on a time course. The cells appear red upon incorporation of the Incucyte
NucRed dye to aid in cellular counts.
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MiaPaca-2 METTL3 knockdown clones were plated in 96-well plates in duplicates in three
independent experiments and allowed to grow in the Incucyte, while being imaged every 4 hours for
5 days. Incucyte NucRed fluorescent dye was added to aid in cellular count. Using the NucRed dye as
a marker to label nuclei, cellular counts over 5 days were used to plot growth curves. Population
doubling times were extracted from the growth curves, using the exponential growth curve equation.
The population doubling times as compared against the non-targeted control are as follows:

Population

MC5

MC6

MC7

MC11

MNT

26.0

27.5

32.5

32.4

21.6

Doubling Time (h)

All MiaPaca-2 METTL3 knockdown clones except clone 6 (MC6) showed a significantly slower
proliferation rate compared to the non-targeted control. The population doubling time of the
knockdown clones being higher than the non-targeted denotes that it takes longer for the clones to
double their population, due to their slower growth rate. We observed that METTL3 knockdown,
hence reduces proliferation rates in most METTL3 knockdown clones, save for one in MiaPaca-2 cells.
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A

B

Figure 15: METTL3 knockdown reduces proliferation rates in MiaPaca-2 single cell clones
A) Growth curve denotes the rate of proliferation in MiaPaca-2 clones upon METTL3
knockdown compared to non-targeted control
B) Doubling times of MiaPaca-2 METTL3 knockdown clones extracted from the growth curve
are depicted in this graph
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4.5 Migration assay

Chemo attractant

Serum free

4.5.1 METTL3 knockdown does not affect the migration rates of Panc-1 cells

PC2

PC5

PC4

PC6

PNT

p=0.76; ns

p=0.37; ns
p=0.32; ns
p=0.23; ns

Figure 16: METTL3 knockdown does not affect migration rates of Panc-1 clones
A) Panc-1 clones that migrated to the bottom of the transwell are shown here post fixing and
staining with crystal violet
B) Bar graph indicates the number of cells that migrated in each of the METTL3 knockdown
clones compared to non-targeted control
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To determine how METTL3 loss affects migration rates of pancreatic cancer cells,we conducted a
transwell migration assay on Panc-1 METTL3 knockdown clones. 10% fetal bovine serum was used as
chemotactic gradient. Panc-1 cells were allowed to migrate through the transwell for 24 hours, post
which they were fixed and stained using crystal violet dye. The fixed and stained cells were observed
under the microscope and images were captured. Automated cell counter as part of Fiji – Image J was
used to count the number of cells that migrated to the bottom of the transwell. We observed no
significant difference in the migration rates of the knockdown clones when compared to the nontargeted control in Panc-1 cells. Though we observed no significant difference in the migration rates
of these cells, three out of the four clones exhibited a slower migratory trend compared to the control.
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Chemo attractant

Serum free

4.5.2 METTL3 knockdown reduces the migration rates of MiaPaca-2 cells

MC5

MC6

MC7
p=0.0123; *

MC11

MNT

p=0.8782; ns
p=0.0041; **
p=0.0043; **

Figure 17: METTL3 knockdown reduces affect migration rates of MiaPaca-2 clones
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A) MiaPaca-2 clones that migrated to the bottom of the transwell are shown here post fixing
and staining with crystal violet
B) Bar graph indicates the number of cells that migrated in each of the METTL3 knockdown
clones compared to non-targeted control

To determine how METTL3 loss affects migration rates of pancreatic cancer cells,we conducted a
transwell migration assay on MiaPaca-2 METTL3 knockdown clones. 10% fetal bovine serum was used
as chemotactic gradient. MiaPaca-2 cells were allowed to migrate through the transwell for 17 hours,
post which they were fixed and stained using crystal violet dye. The fixed and stained cells were
observed under the microscope and images were captured. Automated cell counter as part of Fiji –
Image J was used to count the number of cells that migrated to the bottom of the transwell. We
counted the total number of cells present at the bottom of the transwell and used that as a measure
of the migration rate, since the knockdown clones as well as the non-targeted control were allowed
to migrate for the same duration of time. We observed that the migration rates of three of the METTL3
knockdown clones were significantly slower when compared to the non-targeted control in MiaPaca2 cells. Further investigation is needed to determine the variability in clone 6 and why the migration
rate of that particular clone is higher than the NT control.
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shRNA 113

shRNA 112

shRNA 111

shRNA 110

4.6 Sanger sequencing confirms sequences of shRNAs used to target murine METTL3
gene

Figure 18: Confirming different shRNA plasmid sequences targeting murine METTL3 – Sanger
sequencing results showing the nucleotide sequences of different shRNA plasmid constructs tested
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To investigate the effects METTL3 loss may have on murine pancreatic cancer cells, we sought
to generate a METTL3 knockdown in PKCY cell lines. We purchased four different shRNA plasmid
constructs that target the murine METTL3 gene and tested them to identify the plasmid sequence
that yields in the most genetic knockdown of METTL3 expression. The plasmids were isolated from
bacterial stocks purchased, through a miniprep protocol. The purified plasmid sequences were
verified by performing Sanger Sequencing at the MD Anderson Sequencing Core.
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4.7 Targeting murine METTL3 gene using shRNA 112 yields the least METTL3
expression

110 111 112 113 NT
A

METTL3

70kD

B-ACTIN

42kD
p=0.1373; ns
p=0.0006; ***

B

p<0.0001; ****
p<0.0001; ****

Figure 19: Testing knockdown efficacy of different shRNA lentivirus targeting murine METTL3
A) Western blot showing METTL3 expression levels in PKCY cells when transfected with each
virus
B) Bar graph denotes the level of METTL3 expression in PKCY cells when transfected with each
virus tested. This allows us to identify the lentiviral construct that produces the most
knockdown in METTL3 expression
Four different shRNA plasmids (shRNA110, shRNA111, shRNA 112, shRNA 113) that target murine
METTL3 were tested to determine their knockdown efficacies. We generated lentivirus from each of
the plasmids and transfected one PKCY cell line, 14292 with each of the viruses. Protein from the
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transfected PKCY cells were then collected, and a western blot was run to determine the level of
METTL3 knockdown in the bulk population. We noted that when the 14292 PKCY cells were
transfected with shRNA 112, the level of METTL3 expression was lowest, as shown below:

shRNA virus

Average

Average

METTL3

METTL3 KD

expression

110

70%

30%

111

37%

63%

112

12%

88%

113

29%

71%

This implies that the shRNA 112 plasmid produces the most METTL3 knockdown. To add more
biological replicates, we used the shRNA 112 virus and transfected two more PKCY cell lines, namely
– 16686 and 17315 (genotypes described in Table 5). The METTL3 knockdown bulk cell population of
all the PKCY cells were tested for efficient knockdown. Results of the western blot are as follows:
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16686

14292
14292NT

14292KD

16686NT

METTL3

70kD

B-ACTIN

42kD

17315

17315NT

16686KD

METTL3

70kD

B-ACTIN

42kD

Avg METTL3 KD%

17315KD

70kD

METTL3

42kD

B-ACTIN

14292

16686

17315

88%

53%

84%

Further experiments in the murine context were performed on these PKCY METTL3
knockdown bulk population of cells for these three cell lines.
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4.8 Determining levels of expression of EMT markers:
4.8.1 METTL3 knockdown causes a decrease in E-Cadherin, increase in Vimentin, and does
not affect N-Cadherin in Panc-1 cells

PC2 PC4

PC5 PC6

PNT

A

135kD

E-Cad

42kD

B-actin
p=0.0001; ***

B

p<0.0001; ****
p<0.0001; ****
p=0.013; **

C

Figure 20: E-cadherin expression is reduced in Panc-1 cells upon METTL3 knockdown
A) Western blot denotes a decreased level of E-cadherin expression in the Panc-1 single cell
clones compared to the non-targeted control
B) Bar graph indicates the level of E-cadherin expression in the different Panc-1 single cell
clones upon METTL3 knockdown
C) E-cadherin expression levels are quantified in Table C
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PC2 PC4 PC5 PC6 PNT
A

57kD

Vimentin

90kD

Hsp90
p=0.0174; *
p=0.0328; *

B

p=0.0462; *
p=0.0178; *

C

Figure 21: Vimentin expression is increased in Panc-1 cells upon METTL3 knockdown
A) Western blot denotes an increased level of Vimentin expression in the Panc-1 single cell
clones compared to the non-targeted control
B) Bar graph indicates the level of Vimentin expression in the different Panc-1 single cell clones
upon METTL3 knockdown
C) Vimentin expression levels are quantified in Table C
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PC2

PC4

PC6

PC5

PNT

A

140kD

N-cad

42kD
B-act
p=0.9462; ns
B

p=0.1518; ns
p=0.2059; ns
p=0.0019; **

C

Avg N-cad exp %

PC2

PC4

PC5

PC6

96%

3184%

2692%

611%

Figure 22: N-cadherin expression is not affected in Panc-1 cells upon METTL3 knockdown
A) Western blot denotes an increased level of N-cadherin expression in some Panc-1 single cell
clones compared to the non-targeted control
B) Bar graph indicates the level of N-cadherin expression in the different Panc-1 single cell
clones upon METTL3 knockdown
C) N-Cadherin expression levels are quantified in Table C
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In Panc-1 METTL3 knockdown single cell clones, there is a significant decrease in E-cadherin
expression across all clones and a significant increase in Vimentin expression across all clones when
compared to the non-targeted control.
N-cadherin expression on the other hand, seems to not be influenced by METTL3 loss. One of
the clones, PC6 shows a significant increase in N-cadherin expression upon METTL3 knockdown. Two
of the other clones PC4 and PC5 also show a marked increase in N-cadherin expression, but due to
high variability in the replicates, the expression is not significantly different from the NT control. Even
though the difference is not statistically significant, the overall trend in Panc-1 clones is for an increase
in the expression level of N-cadherin compared to control, in three out of four clones.
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4.8.2 METTL3 knockdown does not affect Vimentin expression in MiaPaca-2 cells

MC5

MC6

MC7

MC11

MNT

A

Vimentin

57kD

Hsp90

90kD
ns

B

ns
ns

ns

C

Avg METTL3 KD%

MC5

MC6

MC7

MC11

147%

128%

109%

145%

Figure 23: Vimentin expression is seemingly increased in MiaPaca-2 cells upon METTL3 knockdown
A) Western blot denotes a seemingly increased level of Vimentin expression in the MiaPaca-2
single cell clones compared to the non-targeted control
B) Bar graph indicates the level of Vimentin expression in the different MiaPaca-2 single cell
clones upon METTL3 knockdown
C) Vimentin expression levels are quantified in Table C
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Vimentin expression in MiaPaca-2 METTL3 knockdown single cell clones, seems to not be
affected. All the clones show a marginal increase in Vimentin expression, but the expression is not
significantly different from the NT control. We can conclude that Vimentin expression is not
affected by METTL3 knockdown.
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4.8.3 Effect of METTL3 knockdown on E-Cadherin, Vimentin, and N-Cadherin expression in
PKCY cells is inconclusive
14292 NT

A

14292 KD 16686 NT 16686 KD 17315 NT 17315 KD

E-cad

135kD

B-Actin

42kD
1.5

ns

E-Cad expression

1.0

ns

0.5

1.0

0.5

0.0

0.0
14292 KD

14292 NT

E-Cad expression

E-Cad expression

1.5

1.5

ns

1.0

n
s

0.5

16686 KD

16686 NT

0.0
17315 KD

Avg E-cad exp %

17315 NT

14292

16686

17315

77%

95%

110%
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ns

10

5

0

0.0
14292 KD

16686 KD

14292 NT

16686 NT

1.5

Vimentin Expression

Vimentin Expression

1.5

17315 KD

57kD

Vimentin Expression

B

17315 NT

1.0

*
0.5

0.0
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16686
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14292 NT 14292 KD 16686 NT 16686 KD 17315 NT 17315 KD

C
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B-Actin
4

N-Cad expression
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1.0

0.5

3
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2
1
0
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Figure 24: Effect of METTL3 knockdown on EMT-associated proteins in PKCY cells is inconclusive
A) Panel A shows the level of E-cadherin expression in METTL3 knockdown PKCY cells and their
respective non-targeted controls
B) Panel B shows the level of Vimentin expression in METTL3 knockdown PKCY cells and their
respective non-targeted controls
C) Panel C shows the level of N-cadherin expression in METTL3 knockdown PKCY cells and their
respective non-targeted controls
We observe that the level of expression of E-cadherin, Vimentin, and N-cadherin remain
uninfluenced by METTL3 loss in PKCY cells. Increase or decrease in expression of EMT-associated
proteins compared to non-targeted control is extensively variable across the different PKCY METTL3
knockdown cell lines. This may be a function of the nature of the PKCY cell line. Be it an epithelial or
mesenchymal-like cell line, having undergone malignant transformation, the way the cell line
responds to METTL3 loss may be highly variable. Moreover, the increase or decrease in expression
levels upon METTL3 knockdown are not significantly different from their respective non-targeted
controls. We must bear in mind that these are METTL3 knockdown cell populations in bulk, not having
had single cell clones cultured from each of them. This result could also be due to the heterogeneity
in knockdown levels in a bulk population. These results cannot hence conclude that METTL3 loss has
absolutely no effect on expression levels of E-cadherin, Vimentin, and N-cadherin. Further studies
with single cell clones of PKCY METTL3 knockdown are needed to observe any potential effects.
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5. Discussion:
Pancreatic Ductal Adenocarcinoma is one of the most aggressive solid cancers, whose treatment
is made more challenging by compounding factors like late diagnosis, rapid metastatic spread, and
chemoresistance. Genetic perturbations are observed in well characterized sets of genes, known as
genetic drivers of the disease. These signature mutational landscapes are commonly observed in high
frequencies across the PDAC patient population. Despite the uniform mutational profiles, treatment
outcomes vary drastically among patients.
Recent studies have brought to attention, the need to therapeutically exploit epigenetic
pathways, apart from only targeting genetic mutations to effectively combat PDAC. Dysregulation of
epigenetic proteins and associated mechanisms have been implicated to contribute to the
progression of the disease. DNA methylation, histone modifications, aberrant microRNA expression
are some avenues of keen therapeutic interest due to the reversible nature of their effects.(43),(44)
METTL3 being an important epigenetic regulator of RNA in the human body, we sought to
understand the broader question of the role METTL3 plays in PDAC progression. We found that
METTL3 expression positively correlates with survival in PDAC patients by analyzing data from the
TCGA-PAAD cohort. Expression of METTL3 can potentially be used as a molecular prognostic factor in
the diagnosis of PDAC. This survival correlation, however, begs the question, is METTL3 playing the
role of a tumor suppressor and being protective in PDAC? We hypothesized that since higher METTL3
expression significantly extends survival by 6 months, presence of METTL3 does impact PDAC
progression. From our in vitro loss of function studies, we find that METTL3 knockdown reduces
proliferation and migration in MiaPaca-2 cells, but only reduces proliferation in Panc-1 cells. These
results are in contradiction to the TCGA survival study, where METTL3 seems to be playing a protective
role.
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METTL3 is crucial in early development and differentiation. It represses pluripotent identity and
induces cell fate specification.(37),(45) In a malignant context, when a tumor undergoes epithelial to
mesenchymal transition (EMT), the restoration of early embryonic transcriptional programs occurs.
Hence, we wanted to understand the role of METTL3 in effecting EMT-associated proteins in PDAC.
We found that in Panc-1 cells, there was a significant reduction in E-cadherin and a concordant
increase in Vimentin upon METTL3 knockdown. The effect was inconclusive in MiaPaca-2 cells. But in
Panc-1 cells, this is consistent with the EMT phenotype, where expression of an epithelial marker is
reduced while expression of a mesenchymal marker is increased. If knocking down METTL3 induces
an EMT-like phenotype, it can be argued that METTL3 plays a potentially protective role in PDAC.
METTL3 has been previously shown to effect pathogenesis in cervical cancer by enriching abundance
of m6A in Snail mRNA, thus inducing EMT in cancer.(41) Given our preliminary results, the mechanism
of how METTL3 affects EMT induction in PDAC requires further investigation.
We must consider that there may also be differences arising due to the nature of the cell lines.
Panc-1 is an epithelial-like cell line whereas MiaPaca-2 is a mesenchymal-like cell line. Incorporating
more biological replicates of the two types of cell lines can help answer the question of if the effect is
dependent on the nature of the cell line. Another consideration to note is that this study used shRNA
knockdown of METTL3 which is not a complete knockout of expression. Since m6A RNA methylation
is highly crucial, the cells may have devised a strategy to compensate for the reduction in methylation
without adverse outcomes. Utilizing METTL3 knockout CRISPR clones of pancreatic cancer cell lines
can be an effective strategy to understand the behaviors of tumors completely devoid of METTL3.
When it comes to the TCGA expression data, patient tissue samples like most pancreatic tumors are,
may have been heterogenous with varied kinds of cell populations. We know that islet cells in the
pancreas express high levels of METTL3. Hence, distinguishing the malignant compartment from
normal pancreas, while performing RNA-Seq expression profiling is key to making an assertion.
61

Methylation is highly dynamic, reversible, and differs based on the tissue type, disease state, and
other pathologies. Studies from other groups have indicated a dual role for METTL3/m6A methylation
in tumors. METTL3 has been shown to be playing tumor promoting roles in lung cancer,(38) gastric
cancer,(46) and acute myeloid leukemia.(47) Whereas in glioblastoma(48), renal cell carcinoma(40),
and breast cancer(49) there is evidence to conclude that METTL3 plays the role of a tumor suppressor.
A 2018 study found that knockdown of METTL3 increased the susceptibility of human pancreatic
cancer cell lines to anti-cancer agents like cisplatin, gemcitabine, and 5-fluorouracil. They concluded
that METTL3 promotes chemoresistance in pancreatic cancer cells.(50) Contradictory to their results,
our study highlights an important clinical finding of patient overall survival positively correlating with
METTL3 in PDAC. This can mean that the effect METTL3/m6A methylation exerts of PDAC must be
examined at different temporal snapshots in the pathogenesis of the disease (initiation versus
progression) to conclude a role with certainty.
Interestingly, independent of the potential effect the m6A writer has on tumor behavior, reader,
and eraser proteins of the m6A methylation cascade have also been implicated in cancers. FTO and
ALKBH5 have both been implicated to be playing tumorigenic roles in glioblastoma.(48),(51) IGF2BP
proteins have been shown to target MYC and promote cellular migration, invasion in liver cancers.(52)
It has also been shown to not always be that the effect an m6A writer and an m6A eraser exert be
counteractive. While METTL3 (writer) acts as an oncogene in AML,(39) FTO (eraser) also acts as an
oncogene in AML.(53) This dynamic interplay between the writers, readers, and erasers should be
further explored for a better mechanistic insight in PDAC. Regardless of the primary site of origin of
the cancer, the volume of implication METTL3 possesses in pathophysiology of cancer, and the
therapeutic potential of understanding its role in the disease are unmistakable.
Methylated RNA Immunoprecipitation sequencing (MeRIP-Seq) is an antibody-dependent
technique to help map m6A sites across the transcriptome.(30) Since METTL3 post-transcriptionally
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affects RNA transcripts, MeRIP-Seq can be performed as future work to delineate the specific
transcripts METTL3 targets. This can give us an insight into what effector pathways METTL3 employs
to bring about the phenotypical effects observed.
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